the differences in outcomes and treatment in cll patients with mutated and unmutated ighv
Published 10 months ago • 367 plays • Length 2:08Download video MP4
Download video MP3
Similar videos
-
2:31
treatment considerations for ighv-unmutated and mutated cll
-
1:43
long-term outcomes of the ifcg regimen for firstline treatment of patients with ighv-mutated cll
-
1:15
outcomes of non-intensive chemotherapy differ for idh1 and idh2-mutated aml
-
2:20
treatment approaches for mutated and unmutated cll
-
1:22
diagnostics and treatment outcomes from primary cbcl
-
1:53
clinical outcomes of btki ven treatment in cll/sll: double-exposed vs double-refractory patients
-
4:02
living with chronic lymphocytic leukaemia (cll)
-
23:44
e07.2 genome wide crispr cas9 screening in immune cells
-
4:27
(video 5 of 8) epigenomics: your epigenome and environment
-
2:25
comparing the outcomes of patients with lbcl receiving allosct versus anti-cd19 car-t therapy
-
1:38
considerations when selecting between jak inhibitors for patients with mpns
-
1:29
the importance of treatment sequencing in cll
-
3:32
cll and covid-19: patient outcomes
-
1:09
sequencing of therapies to improve outcomes of cll patients
-
2:34
sequencing of therapies in patients with r/r cll
-
1:06
phase ib/ii study of viro-t-cell in patients with r/r cml infection after allosct
-
1:18
involving the patient in treatment decisions for cll
-
1:40
mutations in all and their implications for treatment decisions
-
2:41
fixed-duration vs continuous therapy in cll
-
2:47
incidence & clinical significance of clonal hematopoiesis in healthy vs aml patients
-
3:36
the real cost of hematological cancer care explained
-
2:19
long-term management of cll for improved outcomes